Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer

Introduction: The RATIONALE-309 trial confirmed the significant efficacy and safety of tislelizumab plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). However, the economic benefits of this regimen are unclear. Therefore, this study aimed to evaluate the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pei, Zhengda, Xiao, Ningping, Yang, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642263/
https://www.ncbi.nlm.nih.gov/pubmed/37964872
http://dx.doi.org/10.3389/fphar.2023.1265784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642263/
https://www.ncbi.nlm.nih.gov/pubmed/37964872
http://dx.doi.org/10.3389/fphar.2023.1265784

Ejemplares similares